Table 5 Summary of clinical studies on the effect of conditioned medium of mesenchymal stem cells on inflammatory dermatologic diseases
Author(s); Year | Aim of study | Methods | Outcome measures | Results |
|---|---|---|---|---|
Number of patients, injected substance (donor site), the volume of injection, control group, follow-up period | ||||
Kim, 2020 [38] | To evaluate the efficacy of a cream containing human UC-MSC-CM in improving skin barrier function in individuals with atopic dermatitis (AD). | • Participants: 28 individuals (15 men and 13 women) with an average age of 24.68 ± 4.32 years. • Intervention: Application of a UC-MSC-CM cream twice daily for four weeks on both eczematous lesions and unaffected skin. | -Skin surface hydration (SCH), and Transepidermal water loss (TEWL) | SCH Increase: 15.67 AU on eczematous lesions and 14.49 AU on unaffected skin. TEWL Decrease: 15.09 g/m²/h on eczematous lesions and 3.08 g/m²/h on unaffected skin. The findings supported that MSC-CM-based cosmetic products can enhance skin barrier function and may serve as an effective treatment for AD. |
Seetharaman, 2019 [31] | To assess the clinical efficacy of MSC-CM derived from human adipose tissue in the treatment of scalp psoriasis. | Participant: A 38-year-old male with scalp psoriasis. Intervention: Topical application of MSC-CM to affected areas once daily. Follow-up Duration: One month for initial assessment and six months for monitoring relapses or adverse effects. | Psoriasis Scalp Severity Index (PSSI) score, and Presence or absence of relapses and adverse effects. | PSSI Score Improvement: Reduced from 28 to 0 after one month. Long-Term Outcome: No relapses or adverse effects were reported during the six-month follow-up period. |